RAPP (STOCKS)
Rapport Therapeutics, Inc. Common Stock
$34.650000
+0.480000 (+1.40%)
Prev close: $34.170000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Abraham N. Ceesay
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,655.55M
- Employees
- 69
- P/E (TTM)
- -12.09
- P/B (TTM)
- 3.42
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
10
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.72 | $-0.69 | -0.0284 | -4.11% |
|
Sep 2025 (Q3)
|
$-0.71 | $-0.79 | +0.0809 | +10.23% |
|
Jun 2025 (Q2)
|
$-0.75 | $-0.85 | +0.0983 | +11.59% |
|
Mar 2025 (Q1)
|
$-0.68 | $-0.78 | +0.0952 | +12.28% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $13.62M |
| Operating Expenses | $125.10M |
| Research and Development | $94.79M |
| Other Operating Expenses | $30.31M |
| Operating Income/Loss | -$125.10M |
| Income/Loss From Continuing Operations After Tax | -$111.48M |
| Income/Loss From Continuing Operations Before Tax | -$111.48M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$111.48M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$111.48M |
| Net Income/Loss Available To Common Stockholders, Basic | -$111.48M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.86 |
| Diluted Earnings Per Share | -$2.86 |
| Basic Average Shares | 38,934,569 |
| Diluted Average Shares | 38,934,569 |
| Assets | $512.43M |
| Current Assets | $498.56M |
| Cash | $490.50M |
| Other Current Assets | $8.06M |
| Noncurrent Assets | $13.87M |
| Fixed Assets | $2.98M |
| Other Non-current Assets | $10.89M |
| Liabilities | $27.78M |
| Current Liabilities | $19.05M |
| Accounts Payable | $4.19M |
| Wages | $7.12M |
| Other Current Liabilities | $7.74M |
| Noncurrent Liabilities | $8.73M |
| Equity | $484.65M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $484.65M |
| Liabilities And Equity | $512.43M |
| Net Cash Flow From Operating Activities | -$87.47M |
| Net Cash Flow From Operating Activities, Continuing | -$87.47M |
| Net Cash Flow From Investing Activities | -$187.47M |
| Net Cash Flow From Investing Activities, Continuing | -$187.47M |
| Net Cash Flow From Financing Activities | $270.79M |
| Net Cash Flow From Financing Activities, Continuing | $270.79M |
| Net Cash Flow | -$4.16M |
| Net Cash Flow, Continuing | -$4.16M |
| Comprehensive Income/Loss | -$110.42M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$110.42M |
| Other Comprehensive Income/Loss | $1.07M |
| Other Comprehensive Income/Loss Attributable To Parent | $1.07M |